Oxford Biomedia to Present Research Around Gene Therapies for Parkinson’s

LONDON - Sept. 12, 2013 - PRLog -- This information could tentatively enable not only earlier diagnosis of the disease but also therapies targeted at optimising patients’ health.

It is estimated that 7 to 10 million people worldwide are living with Parkinson’s disease (PM LiVE, 2013). There is currently no drug that has been proven to cure the disease or delay its development. However, there is exciting new research afoot in gene therapies which looks set to revolutionise therapies for treating neurodegenerative diseases such as Parkinson’s.

This conference will discuss this and many novel case studies on treatment of Parkinson's disease.

Key speakers will include:

•   Kyriacos Mitrophanous, Head of Research, Oxford BioMedica plc
•   Richard Wyse, Director of R&D, The Cure Parkinsons Trust
•   Henri Huttunen, Chief Scientific Officer, Hermo Pharma Ltd
•   Warren Hirst, Associate Research Fellow & Group Leader, Pfizer

Clinical Trials in CNS will also feature a presentation on early detection of Alzheimer's Disease in Mid-life lead by Craig Ritchie, Clinical Senior Lecturer, Imperial College London, highlighting pathological changes in mid-life which lead to dementia in older people and outline UK-based infrastructure initiatives to support translational medicine innovations in dementia research around mid-life and early dementia.

The conference will aim to provide attendees with:

•   Presentations on the importance of understanding the pathophysiology and biology of disease processes with use of biomarkers and imaging techniques
•   How to discover ways in which to design late stage clinical trials
•   Information on how to overcome challenges of delivery within the CNS
•   Discussions on the legal and ethical issues behind sham surgery

Attendees can also attend a half day workshop held on 20th November which will be on: Defining Clinical Relevance. Led by QCTR, the workshop will examine how to develop a better awareness of the limitations of primary outcome measures in neurological diseases and how to select and make a case to regulatory authorities for a single efficacy outcome measure.

Sponsors for the event will also include: Bracket, Cytox, Hermo Pharma & QCTR

For the full conference programme and further information please visit:
http://www.smi-online.co.uk/goto/clinicaltrialscns57.asp for more information or Contact Jonathan Collins on +44 (0)20 7827 6734 or email: jcollins@smi-online.co.uk
Sponsorship opportunities are available for this event, please contact Alia Malick on +44(0) 20 7827 6168.

Contact for media-partners: Teri Arri, tarri@smi-online.co.uk, +44 (0) 20 7827 6072

Clinical Trials in CNS
18th & 19th November 2013, Marriott Regents Park Hotel, London
http://www.smi-online.co.uk/goto/clinicaltrialscns57.asp
Follow us on Twitter @smipharm

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.
For more information, please visit www.smi-online.co.uk